TD Asset Management Inc. Has $6.08 Million Stake in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

TD Asset Management Inc. grew its position in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) by 11.3% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 91,258 shares of the company’s stock after buying an additional 9,292 shares during the quarter. TD Asset Management Inc. owned approximately 0.20% of Zentalis Pharmaceuticals worth $6,081,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. Macquarie Group Ltd. bought a new position in shares of Zentalis Pharmaceuticals in the 2nd quarter valued at approximately $28,000. O Shaughnessy Asset Management LLC bought a new position in shares of Zentalis Pharmaceuticals in the 2nd quarter valued at approximately $62,000. Nisa Investment Advisors LLC bought a new position in shares of Zentalis Pharmaceuticals in the 2nd quarter valued at approximately $89,000. Meeder Asset Management Inc. increased its position in Zentalis Pharmaceuticals by 1,634.7% in the 3rd quarter. Meeder Asset Management Inc. now owns 2,047 shares of the company’s stock worth $137,000 after buying an additional 1,929 shares during the period. Finally, FORA Capital LLC bought a new position in Zentalis Pharmaceuticals in the 2nd quarter worth approximately $143,000. Institutional investors and hedge funds own 90.92% of the company’s stock.

In other Zentalis Pharmaceuticals news, insider Alexis Pinto sold 30,000 shares of the stock in a transaction dated Monday, October 25th. The stock was sold at an average price of $77.73, for a total value of $2,331,900.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Kevin D. Bunker sold 10,000 shares of the stock in a transaction dated Monday, January 10th. The stock was sold at an average price of $68.41, for a total value of $684,100.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 165,413 shares of company stock valued at $12,689,830. 21.00% of the stock is currently owned by corporate insiders.

A number of analysts have recently issued reports on ZNTL shares. HC Wainwright boosted their price objective on Zentalis Pharmaceuticals from $80.00 to $120.00 and gave the company a “buy” rating in a research report on Thursday, November 11th. They noted that the move was a valuation call. Stifel Nicolaus started coverage on Zentalis Pharmaceuticals in a research report on Wednesday, September 29th. They set a “buy” rating and a $84.00 price objective on the stock. Wedbush restated an “outperform” rating and set a $89.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Thursday, November 11th. Zacks Investment Research raised Zentalis Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, November 17th. Finally, Oppenheimer began coverage on Zentalis Pharmaceuticals in a research note on Tuesday, September 28th. They issued an “outperform” rating and a $90.00 price target on the stock. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $95.17.

Zentalis Pharmaceuticals stock opened at $67.54 on Friday. The firm has a market cap of $3.06 billion, a P/E ratio of -18.35 and a beta of 1.75. The business’s fifty day moving average is $76.74 and its two-hundred day moving average is $67.25. Zentalis Pharmaceuticals, Inc. has a 52 week low of $34.48 and a 52 week high of $87.19.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its earnings results on Wednesday, November 10th. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.31) by $1.22. As a group, equities analysts forecast that Zentalis Pharmaceuticals, Inc. will post -4.22 EPS for the current year.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidates are the ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer; and ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, as well as in Phase 1b clinical trial in combination with chemotherapy in patients with advanced ovarian cancer.

Further Reading: Guidelines for Successful Channel Trading

Institutional Ownership by Quarter for Zentalis Pharmaceuticals (NASDAQ:ZNTL)

Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.